DAAs produce cure rates in HCV/HIV co-infection similar to monoinfection

Using direct-acting antiviral therapies demonstrated similarly high rates of sustained virologic response for hepatitis C virus infection in patients with and without HIV infection as compared with rates for HCV mono-infected patients, according to findings published in Hepatology. “Because of low [sustained virologic response] rates associated with interferon-based therapies, the accelerated progression of HCV related liver disease, and barriers to recei

The Week in Review: October 13 – October 20, 2017

Friday, October 20, 2017 News Recap: Disease Management: Women: Hepatitis C in pregnancy: screening, treatment, and management. Hepatitis C (HCV) during pregnancy is associated with serious, adverse outcomes. Infants born to women with HCV are more likely to experience fetal growth restriction and low birth weight. For women, chronic HCV is associated with progressive liver damage and, during pregnancy, can be transmitted from the mother to the fe...

Cannabis May Be Protective Against Steatosis in Persons Coinfected with HIV-HCV

MARSEILLE, FRANCE — Cannabis may be protective against liver disease in subjects infected with both the hepatitis C virus (HCV) and the human immunodeficiency virus (HIV), according to data published online ahead of print in the Journal of Viral Hepatitis. French investigators assessed the relationship between cannabis use and the prevalence of steatosis (fatty liver disease) in a cohort of 838 HIV-HCV co-infected subjects. They reported, “Daily cannab

The Week in Review: October 6 – October 13, 2017

Friday, October 13, 2017 News Recap: Research & Discoveries After an intense hunt, researchers at the Norwegian University of Science and Technology (NTNU) can now describe an important part of the disease's guerrilla tactics: how hepatitis C converts innocent cells into outright virus factories.  How hepatitis C hides in the body. Apparently, liver cancer can be caught at an early stage through a newly developed blood test, improving the odd...

Rapid fibrosis progression in large proportion of HIV-positive gay men after acute HCV

Over a third of HIV-positive gay men develop significant liver fibrosis after an episode of acute hepatitis C virus (HCV) infection, German investigators report in the Journal of Viral Hepatitis. Over three years of follow-up, 39% of individuals developed fibrosis stage F2 or higher. Risk factors included older age, alcoholism and non-response to therapy based on interferon during acute infection. Highly effective HCV therapy using direct-acting antiviral

The Week in Review: September 22 – September 29, 2017

Friday, September 29, 2017 News Recap: Merck discontinues HCV programs. There were rumours, but now it’s official: Merck has announced that it will discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection. In a statement the company said the decision was made based on a review of available Pha...

The Week in Review: September 15 – September 22, 2017

Friday, September 22, 2017 News Recap: Access to Treatment: This was a good week in terms of treatment access (but not, unfortunately, in terms of weather or seismic activity: How very, very sad).  Imagine being sick or on treatment in one of these stricken areas! In Canada Epclusa was approved for use in persons co-infected with HIV. This is very good news. Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpat...

Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV

– New Data for First Approved Pan-genotypic Once-Daily Single Tablet Regimen for  Chronic Hepatitis C Virus Infection – MISSISSAUGA, ON, Sept. 21, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for updated labeling of EPCLUSA® (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults w...

The Week in Review: July 28 – August 4, 2017

Friday, August 4, 2017 Treatment: This last week saw the approval in the U.S. of AbbVie’s Mavyret, a pangenotypic also indicated as recuperation therapy for those with GT1 who have failed treatment with DAAs. U.S.: FDA approves Mavyret for Hepatitis C As well, the FDA has approved updated labeling for Epclusa to include use in patients co-infected with HIV. U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatmen...

U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved updated labeling for Epclusa® (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV. “HCV co-infection remains a major cause